The TARGET Study.

The TARGET Study

CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
Interventional Radiology / Interventional Oncology / Latest Evidence / Target Study

 

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.

Lam, Marnix. A Global Study of Advanced Dosimetry in the Treatment of Hepatocellular Carcinoma with Yttrium-90 Glass Microspheres: Analyses from the TARGET Study. Presented at SIR. March 25, 2021

 


Study Objective


Establish the relationships between:

  • Normal tissue adsorbed dose (NTAD) and occurrence of grade 3 or higher hyperbilirubinemia
  • Tumor absorbed dose (TAD) and Objective Response Rate (ORR)
  • TAD and Overall Survival (OS)

 

Study Design


Key Patient Characteristics

  • Mainly Intermediate and Advanced HCC: 33% BCLC B and 55% BCLC C
  • 7cm median target lesion
  • 33% PVT

Dosimetry Approach

  • Investigator review of patient chart and dosimetry calculation
  • Retrospective dosimetry evaluation with multi-compartment approach using Simplicit90Y™ personalized dosimetry software to determine TAD and NTAD

 

Results


Tumor Absorbed Dose Was Predictive of Response1,2

Tumor Absorbed Dose Was Predictive of Overall Survival

Low Rate of ≥ Grade 3 Hyperbilirubinemia Confirms Safety of TARGET Study

The TARGET Study Patient Characteristics 1.
 
The TARGET Study Patient Characteristics 2.
 colored background

Study Takeaways

Deliver the highest dose to the tumor that is safely possible to maximize patient response and improve survival
Predictable results across 8 countries using multi-compartmental dosimetry using Simplicit90Y personalized dosimetry software
Like the LEGACY study and DOSISPHERE-01 trial results, the TARGET study reinforces the association between higher tumor absorbed dose and clinical outcomes
THERASPHRER™

Perform SIRT with TheraSphere™

SIMPLICIT<sup>90</sup>Y™

SIMPLICIT90Y™

Embrace Y90
SIRT Personalised Dosimetry
Physician Education

Virtual Events

Virtual Events

View our latest virtual symposia and webinars on interventional oncology topics. 
Stay up to date

Stay up to date

Stay up to date

Receive emails about the latest interventional oncology news, innovations and events.
Top